StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

Stock analysts at StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued on Wednesday. The firm set a “hold” rating on the stock.

TherapeuticsMD Stock Performance

TXMD opened at $1.78 on Wednesday. The stock’s fifty day simple moving average is $1.74 and its 200 day simple moving average is $1.99. TherapeuticsMD has a 1-year low of $1.43 and a 1-year high of $3.82.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter. The firm had revenue of $0.23 million for the quarter.

Hedge Funds Weigh In On TherapeuticsMD

A number of large investors have recently made changes to their positions in the company. Clearline Capital LP increased its position in TherapeuticsMD by 18.9% during the 2nd quarter. Clearline Capital LP now owns 636,622 shares of the company’s stock worth $1,025,000 after buying an additional 101,282 shares during the period. Prosperity Consulting Group LLC bought a new position in TherapeuticsMD during the first quarter worth about $56,000. Finally, ADAR1 Capital Management LLC acquired a new stake in TherapeuticsMD in the 4th quarter worth about $612,000. Institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.